Abstract
IntroductionIncretin-based therapies, that is, glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors, are relatively novel antihyperglycaemic drugs that are frequently used in type 2 diabetes management. Apart from...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have